Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Capital Expenditures: 2020-2025

Historic Capital Expenditures for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Sep 2025 value amounting to $187,000.

  • Mirum Pharmaceuticals' Capital Expenditures rose 3.31% to $187,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $374,000, marking a year-over-year decrease of 64.07%. This contributed to the annual value of $993,000 for FY2024, which is 811.01% up from last year.
  • As of Q3 2025, Mirum Pharmaceuticals' Capital Expenditures stood at $187,000, which was up 48.41% from $126,000 recorded in Q2 2025.
  • Mirum Pharmaceuticals' Capital Expenditures' 5-year high stood at $779,000 during Q2 2024, with a 5-year trough of $3,000 in Q1 2021.
  • Its 3-year average for Capital Expenditures is $161,778, with a median of $68,000 in 2023.
  • Per our database at Business Quant, Mirum Pharmaceuticals' Capital Expenditures plummeted by 96.94% in 2021 and then surged by 7,966.67% in 2022.
  • Mirum Pharmaceuticals' Capital Expenditures (Quarterly) stood at $3,000 in 2021, then soared by 7,966.67% to $242,000 in 2022, then soared by 300.00% to $68,000 in 2023, then surged by 1,045.59% to $20,000 in 2024, then increased by 3.31% to $187,000 in 2025.
  • Its Capital Expenditures stands at $187,000 for Q3 2025, versus $126,000 for Q2 2025 and $41,000 for Q1 2025.